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Introduction
Repairing facial bone defects, either caused by con-
genital deficiency, trauma or tumor ablation, has been
a challenge for oral and maxillofacial surgeons for a
long time. Several techniques have proven successful.
However, complications such as donor site morbidity
and chronic pain have been reported with the use of
autograft material. The use of tissue-engineering triad
concepts, including stem cells with osteogenic poten-
tial, scaffold and growth factor, to achieve osteogene-
sis in facial and cranial bone reconstruction is now
under extensive study. However, to ensure that stem
cells remain in the recipient site, a biocompatible carrier
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is needed to transfer the stem cells. Recently, some oral
and maxillofacial surgeons have tried to implant bone
marrow, platelet-rich plasma or stem cells to facial
bone defects along with other substances, i.e. hydroxy-
apatite (HA), tricalcium phosphate (TCP), macro-
porous biphasic calcium phosphate (MBCP), or fibrin
glue, to achieve bone regeneration.1–5
MBCP is composed of 60% HA and 40% TCP. HA
provides long-term stability and TCP releases ions that
form acellular apatite crystals. The macroporosity of
MBCP allows cells to penetrate material to a thickness
of 2–3 mm.6–9 One animal study evaluated MBCP
grafted with bone marrow in a high-dose-irradiated
area. The result showed 6-fold new bone formation
compared to MBCP alone.6
Fibrin glue application to decrease intraoperative
bleeding and promote hemostasis has been used widely.
Autologous fibrin glue contains 2 major components:
fibrinogen and thrombin.10–12 Fibrinogen is an abun-
dant plasma protein, produced in the liver. The intact
protein has a molecular weight of 340 kD. It is com-
posed of 3 pairs of disulfide-bound polypeptide chains
named alpha, beta and gamma. Proteolysis by thrombin
results in fibrin monomers that are polymerized in a
half-overlap fashion to form insoluble fibrin fibrils. The
other major component in autologous glue is thrombin.
Thrombin is an endoprotease that naturally functions
as a blood clotting factor to convert fibrinogen to fib-
rin. Within seconds after fibrinogen and thrombin are
mixed together, they form a gel-like component.10–12
Although the role of fibrin glue alone in interosseous
and osteochondral healing remains debatable,13,14
it is now administrated as a scaffold in some tissue
engineering triads in vitro and in vivo.
Stem cells may differentiate into osteogenic cells by
some growth factors. Insulin-like growth factor and
bone morphogenic proteins help regenerate bone.15,16
Other factors that enhance soft tissue healing are those
rich in platelets. Platelets present huge reservoirs of
growth factors for bone regeneration. Platelet-derived
growth factor (PDGF) may initiate connective tissue
healing.17 PDGF also increases mitogenesis, angio-
genesis and macrophage activation.15,18–20
Another growth factor is transforming growth 
factor-β, which increases the chemotaxis and mito-
genesis of osteoblast precursor cells and also stimu-
lates osteoblast deposition.21,22 However, these growth
factors are only effective for a short period after trans-
plantation in vivo.15
The purpose of the present study was to compare
the effectiveness of autologous fibrin glue and MBCP
as carriers in the osteogenesis process with/without
rat mesenchymal stem cells (rMSCs).
Methods
Animal preparation
Fifteen New Zealand white rabbits, average weight
2.5–3.2kg, were used in this study, which was approved
by Taichung Veterans General Hospital’s Animal
Research Committee.
Mesenchymal stem cell preparation
Rabbit bone marrow was harvested from the iliac
bone by using a bone needle with heparin-containing
saline. The mononuclear cells were isolated from the
whole marrow sample by centrifugation across a Ficoll-
Hypaque gradient (Sigma, St Louis, MO, USA), and
were resuspended in α-minimal essential medium con-
taining 20% fetal bovine serum (Flow Laboratories,
Rockville, MD, USA), L-glutamine and penicillin-
streptomycin (Gibco BRL, Rockville, MD, USA). They
were plated at an initial density of 2 × 104 cells/cm3
for culture. The third generation of mesenchymal stem
cells was used in the study. The concentration of cells
was controlled at 1×107 cells/mL. Rabbit mesenchymal
stem cells were then seeded onto 8-chambered slides
(1×105 cells/well) (Corning, Invitrogen, Corning,
NY, USA). The mesenchymal cells were identified by
their surface phenotype: CD34(−), CD133(−) and
CD105(+).
Autologous fibrin glue preparation
Ten mL of autologous blood drawn from each rabbit
was combined with 1 mL of anticoagulant citrate dex-
trose phosphate to prevent coagulation. The blood
was centrifuged at 1,500 rpm for 10 minutes at ambi-
ent temperature to separate the plasma containing the
platelets from the red cells and buffy coat. Using a
modified version of the autologous fibrin glue prepa-
ration method in Thorn et al’s study,23 we extracted
the fibrinogen from the plasma using cold ethanol
precipitation. Thrombin was produced from diluted
plasma by precipitation of euglobulins at low pH. One-
tenth of the platelet-rich plasma was separated for
thrombin preparation. The euglobulin fraction was
precipitated by dilution with citric acid. After thor-
ough mixing of the solution, the tube was centrifuged
at 3,000g for 5 minutes at 4°C. The supernatant was
removed and the precipitate was dissolved in CaCl2
(0.1 M). The pH was adjusted to neutral values by
NaHCO3, and the activation of prothrombin to throm-
bin was started. During the next 3–10 minutes, a fibrin
clot was formed. The clot was gently squeezed during
the gel formation process. After 20–30 minutes, clot
formation was terminated and the liquid thrombin solu-
tion was removed by syringe. To avoid contamination,
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these procedures were performed in a laminar air flow
bench.
Animal surgical procedure
The rabbits underwent general anesthesia by intra-
muscular injection of atropine 0.1 mg/kg, ketamine
50mg/kg and Romfom 5mg/mL with standard mon-
itoring. Each rabbit’s fur was shaved over the opera-
tion site and draped in a sterile fashion. Mesenchymal
stem cells and autologous fibrin glue were harvested
from the iliac bone and peripheral blood. According
to Aghaloo et al’s study design,1 3 cranial defects with
a diameter of 6 mm each were created over the cranial
bone in each rabbit. The 15 animals were separated
into 2 groups. The first group contained 12 rabbits.
The grafted substances placed over the regions of
defect were: (1) stem cells plus fibrin glue; (2) stem
cells plus MBCP (Biomatlante, Vigneux de Bretagne,
France); (3) defect alone. In the second group of 
3 rabbits, the cranial defects were grafted with: (1)
autologous fibrin glue alone; (2) MBCP alone; (3)
defect alone (Figure 1). After implantation, the dura
was first closed by using 4-0 vicryl to prevent graft
material displacement, and 4-0 nylon was then used to
suture the skin layer. The rabbits recovered without
complications after anesthesia subsided.
Results
Clinical evaluation
All rabbits remained healthy before being sacrificed
with intravenous pentobarbital 100 mg/kg at 1, 2 and
3 months post operation. Fibrous tissue was observed
to have extended to the defect on clinical observation
(Figure 2). The defect margin became difficult to iden-
tify 3 months after operation. MBCP particles remained
in the cranial defect 3 months postoperatively.
Radiologic examination
Radiographs were taken of each rabbit’s cranium before
histologic sections were examined. The defects with
graft implantation were increasingly radio-opaque at
1, 2 and 3 months after surgery. More radio-opacity
presented in the MBCP group due to the MBCP par-
ticles that remained. The margin of the defect was diffi-
cult to identify 3 months postoperatively (Figure 3).
Histologic examination
Specimens were treated with hydrochloric acid de-
calcifying solution and then dehydrated with graded
Figure 1. Rabbit cranial defects. The grafted substances placed
over the defects were: macroporous biphasic calcium phosphate
particles (upper left); fibrin glue (upper right); defect alone (bottom).
A B C
Figure 2. Cranial defects after sacrifice of the rabbits at postoperative: (A) 1 month; (B) 2 months; and (C) 3 months. Macroporous
biphasic calcium phosphate particles are still present at 3 months post operation.
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alcohols and embedded in paraffin. They were subse-
quently sectioned at 6 µm with a steel knife. Histologic
specimens were prepared in the usual fashion with
hematoxylin and eosin staining. Bone remodeling and
regeneration were present around the peripheral cra-
nial defect. In the fibrin glue plus rMSC group, more
new bone formation was present compared to the con-
trol group and the fibrin glue alone group. Osteoblasts
rimmed the peripheral defect and new bone forma-
tion at the central portion of the defect was noted in
the fibrin glue plus rMSC group 2 months postopera-
tively. In addition, at 2 months post operation, residual
fibrin glue was still present and mature lamellar bone
formation was noted (Figures 4 and 5). The fibrin glue
plus rMSC group had more bone formation compared
to the other groups. Furthermore, in the MBCP plus
rMSC group, there was inflammatory cell accumula-
tion, including histiocytes, eosinophils and lympho-
cytes. The MBCP plus rMSC group showed more
tissue reaction than the implantations of the MBCP-
alone group. Maximum inflammation was noted at 
2 months post operation. The inflammatory condition
seemed to begin to subside 3 months postoperatively.
Discussion
The tissue-engineering triad concept has been employed
in many animal studies and clinical practice to recon-
struct maxillofacial defects. Different facial regions need
different scaffold modalities.24–26 In von Arx et al’s
study, TCP demonstrated 70% new bone formation at
24 weeks, compared to 54% in the autografted site.27
Alloplast material can be used to reconstruct the defect
and achieve new bone formation. However, many sur-
geons are still concerned about the biocompatibility
of alloplast material. Several studies have investigated
the inflammatory response to biphasic calcium phos-
phate, which is composed of HA and TCP.28 Fibrous
tissue encapsulation of biphasic calcium phosphate
microparticles was observed in Fellah et al’s study.29
They found that micro biphasic calcium phosphate
(pore size <20µm) caused more inflammation and giant
cell accumulation than the intermediate and macro
pore sizes (40–80 µm and 80–200 µm, respectively).
However, we found that MBCP plus rMSC could
cause foreign body reaction, with accumulation of
lymphocytes, plasma cells and histiocytes. MBCP still
remained 3 months postoperatively.
Regarding cytotoxicity, some studies showed that
due to the release of microparticles, cell damage oc-
curred around the implanted biphasic bioceramic.30,31
In our study, stem cells did not present at 1 month
after implantation with MBCP. Although MBCP may
release microparticles that cause inflammation and
impair cell vitality, our study showed that inflammation
subsided after 3 months post operation. In another
animal study, De Kok et al32 mixed mesenchymal
stem cells with HA/TCP, and then placed the mix-
ture in a beagle dog’s extraction socket. Mild inflam-
mation was present 7 days post operation, but had
diminished by postoperative day 21. In our study, the
rMSC plus MBCP group had delayed inflammation 
2 months postoperatively. Viable cell adhesion on the
biphasic calcium phosphate granules was low in some
studies.29,31,32
Fibrin glue contains approximately 10 times the
concentration of fibrinogen, F-VIII, vWF, F-XIII and
A B C
Figure 3. Radiographs of the rabbit craniums at postoperative: (A) 1 month; (B) 2 months; and (C) 3 months. Macroporous biphasic 
calcium phosphate (MBCP) particles are still present at 3 months post operation. There is increased radio-opacity in the MBCP + rat
mesenchymal stem cells (rMSCs) (upper left defect) and fibrin glue + rMSCs (upper right defect), compared to the defect alone (bottom).
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fibronectin of fresh frozen plasma.9,33 One in vitro
study showed that fibrin glue may increase cell-seeding
efficiency to collagen scaffolds and cells may appear
fibroblastic in shape. However, when fibrin glue alone
was used as a scaffold, the cells were spherical.34 An
osteoblast rim around the new bone was also found.
Whether fibrin glue alone can be a strong scaffold
depends on its implantation location. In the rabbit
cranial defects in our study, it was surrounded by hard
tissue. Hard tissue may also enhance the scaffold poten-
tial of fibrin glue. Fibrin glue has no inhibitory effect
on cell morphology, growth, proliferation or differen-
tiation. It has good biocompatibility and can be used
as scaffold material for bone marrow mesenchymal
stem cells in bone tissue engineering.35 The half life
of the fibrin clot was around 4.6 days, and it had
completely disappeared from the body within 30 days
in some studies.36,37 One study claimed that com-
mercially produced fibrin glue could degrade within
1–2 weeks.37 However, in our study, residual fibrin
glue still remained 2 months after implantation and
no granulation tissue reaction was found (Figure 4).
This may be because the fibrin glue had been placed
in a defect surrounded by hard tissue, delaying its
degradation.
Cloning experiments have shown that mesenchy-
mal stem cells fail to proliferate beyond 20 population
doublings.38 When an adequate cell number has been
achieved, re-implantation to the defect should be per-
formed. The stem cells were cultured in vitro before
operation. The concentration of cells was controlled at
1 × 107 cells/mL. No rMSCs remained in the cranial
defect 1 month postoperatively, and osteoblasts rim-
ming the new bone in the central part of the defect were
found 2 months postoperatively (Figure 5). Using stem
cells in various ways to mobilize the damaged organ
seems to be a promising modality.39–42 Some clinical
studies used autologous peripheral blood stem cell trans-
plantation, combined with chemotherapy/radiotherapy,
to treat chemosensitive malignant disease (i.e. acute
myeloid leukemia) and got good responses.43,44
Osteoblasts can be enticed to move across a greater
distance by creating a scaffold system. The movement
of osteoblasts along the fibrin network results in the
formation of woven bone much earlier than usual.
Using fibrin glue as a scaffold plus rMSCs resulted in
earlier and more mature new bone formation compared
to using fibrin glue alone (Figure 5).
Researchers have tried using mixed scaffolds of
fibrin glue with calcium phosphate ceramic granules
or MBCP. In some studies, new bone formation was
found on the periphery of the bony defect, and these
scaffolds provided more stable structure.7,39 Although
new bone formation was also found when using MBCP
or MBCP plus rMSCs, inflammatory cell accumu-
lation around the new bone also occurred. This can
Figure 5. Histologic examination with hematoxylin and eosin staining; original magnification 100×. c = control; W = week; D = defect; 
F = fibrin glue; M = macroporous biphasic calcium phosphate; S = mesenchymal stem cells. (H) c8WF: new bone formation at the center
of the defect, interacting with fibrin glue. (N) c12WF: Mature bone formation at the central defect; no fibrin glue remains. (K) 8WF + S:
new bone formation, interacting with fibrin glue; osteoblast present at periphery of new bone. (Q) 12WF + S: mature new bone formation
at the central defect. (I) c8WM: new bone formation. (O) c12WM: mature bone formation, connecting to peripheral bone. (L) 8WM + S:
histiocytes, eosinophils, lymphocytes and plasma cells encroach MBCP particles. (R) 12WM + S: new bone formation, surrounded by
lymphocytes and histiocytes.
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compromise the quality of the new bone when fur-
ther fixture implantation is considered. In Bluteau 
et al’s study,9 osteoblasts covered the MBCP, which
was coated with thrombin or fibrinogen. However,
very few cells were observed on the surface of MBCP
covered with Tissucol® on scanning electron micros-
copy study. The surface of MBCP needs to be coated
with fibrinogen or thrombin to increase osteoblast
adaptation. In clinical application, using 2 or more scaf-
folds increases the cost and difficulty of the operation.
For a non-critical sized defect, using fibrin glue with
stem cells can simplify the early osteogenic procedure.
The sample size in our study was small: only 15
rabbits were used. More inflammation was present in the
MBCP alone and rMSC plus MBCP groups. Using fib-
rin glue with mesenchymal stem cells resulted in earlier
and more mature new bone formation. In cranial–
facial bone reconstruction, autologous fibrin glue com-
bined with osteogenic mesenchymal stem cells may
have a promising role in the future.
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